This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Successful Treatment With Eflornithine

Ann M. Petru, MD; Parvin H. Azimi, MD; Susan K. Cummins, MD, MPH; Albert Sjoerdsma, MD, PhD

Am J Dis Child. 1988;142(2):224-228.

Abstract
• The traditional treatment of African sleeping sickness (trypanosomiasis) with central nervous system involvement Is an organic arsenical compound, melarsoprol, which is associated with severe and even life-threatening side effects. A polyamine biosynthesis inhibitor, eflornithine (chemical name, DL--difluoromethylornithine, supplied as monohydrochloride monohydrate), was used to treat a 3-year-old child with newly diagnosed severe trypanosomiasis that had been acquired more than two years previously in Zaire or the Congo. Treatment consisted of 300 to 400 mg/kg/d of eflornithine by continuous Intravenous infusion for 25 days followed by 300 mg/kg/d of eflornithine by mouth divided in four equal doses daily for 17 days. The child's recovery was dramatic, with eradication of blood and cerebrospinal fluid parasites in the first week. Cerebrospinal fluid pleocytosis resolved completely. Her generalized adenopathy and fever gradually resolved. Severe ataxia, Inability to walk or to change posture on her own, marked language regression, and lethargy all improved during and after her therapy. The drug was well tolerated; the only noted adverse effect was transient thrombocytopenia during the fourth week of therapy. Eflornithine was a safe and effective agent for treatment of trypanosomiasis with central nervous system involvement in this child.

(AJDC 1988;142:224-228)

Author Affiliations
From the Department of Infectious Diseases, Children's Hospital Oakland, Calif (Drs Petru and Azimi); the Department of Epidemiology and International Health, School of Medicine, University of California at San Francisco (Dr Cummins); and the Merrell Dow Research Institute, Cincinnati (Dr Sjoerdsma).

Footnotes
Accepted for publication Aug 3, 1987.

Read in part before the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, Oct 1, 1985.

Reprint requests to Children's Hospital Oakland, 747 52nd St, Oakland, CA 94609 (Dr Petru).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Case 20-2002 - A 37-Year-Old Man with Fever, Hepatosplenomegaly, and a Cutaneous Foot Lesion after a Trip to Africa
Moore et al.
NEJM 2002;346:2069-2076.
FULL TEXT